Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V

Archives of Internal Medicine

Volumn 167, Issue 19, 2007, Pages 2054-2060

  Reynolds, Harmony R ^a,f   Farkouh, Michael E ^a   Lincoff, A Michael ^b   Hsu, Amy ^b   Swahn, Eva ^c   Sadowski, Zygmunt P ^d   White, Jennifer A ^b,e   Topol, Eric J ^b   Hochman, Judith S ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d INSTITUTE OF CARDIOLOGY   (Poland)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RETEPLASE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEATH; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; REVASCULARIZATION; SEX DIFFERENCE;

AGED; ANTIBODIES, MONOCLONAL; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; RECOMBINANT PROTEINS; RECURRENCE; RISK FACTORS; SEX FACTORS; STATISTICS, NONPARAMETRIC; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 35748962934     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.19.2054     Document Type: Article

References (43)

1. Carrabba N, Santoro GM, Balzi D, et al; AMI-Florence Working Group. In-hospital management and outcome in women with acute myocardial infarction (data from the AMI-Florence Registry). Am J Cardiol. 2004;94(9):1118- 1123.
2. Cheng CI, Yeh KH, Chang HW, et al. Comparison of baseline characteristics, clinical features, angiographic results, and early outcomes in men vs women with acute myocardial infarction undergoing primary coronary intervention. Chest. 2004;126(1):47-53.
3. Moen EK, Asher CR, Miller DP, et al; Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Long-term follow-up of gender-specific outcomes after thrombolytic therapy for acute myocardial infarction from the GUSTO-I trial. J Womens Health. 1997;6(3):285-293.
4. Weaver WD, White HD, Wilcox RG, et al; GUSTO-I Investigators. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. JAMA. 1996;275(10):777-782.
5. White HD, Barbash GI, Modan M, et al; Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Study. After correcting for worse baseline characteristics, women treated with thrombolytic therapy for acute myocardial infarction have the same mortality and morbidity as men except for a higher incidence of hemorrhagic stroke. Circulation. 1993;88(5, pt 1):2097-2103.
6. Woodfield SL, Lundergan CF, Reiner JS, et al. Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol. 1997;29(1):35-42.
7. Maynard C, Litwin PE, Martin JS, Weaver WD. Gender differences in the treatment and outcome of acute myocardial infarction: results from the Myocardial Infarction Triage and Intervention Registry. Arch Intern Med. 1992;152(5):972-976.
8. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: a report from the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 1998;98(13):1279-1285.
9. Malenka DJ, Wennberg DE, Quinton HA, et al; Northern New England Cardiovascular Disease Study Group. Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994 to 1999. J Am Coll Cardiol. 2002;40(12):2092-2101.
10. Tamis-Holland JE, Palazzo A, Stebbins AL, et al; GUSTO II-B Angioplasty Substudy Investigators. Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy. Am Heart J. 2004;147(1):133-139.
11. Hochman JS, Tamis JE, Thompson TD, et al; Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med. 1999;341(4):226-232.
12. Van de Werf F, Barron HV, Armstrong PW, et al; ASSENT-2 Investigators. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001;22(24):2253-2261.
13. Berkowitz SD, Granger CB, Pieper KS, et al; Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. Circulation. 1997;95(11):2508-2516.
14. Yip HK, Wu CJ, Chang HW, et al. Cardiac rupture complicating acute myocardial infarction in the direct percutaneous coronary intervention reperfusion era. Chest. 2003;124(2):565-571.
15. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357(9272):1905-1914.
16. Armstrong PW, Chang WC, Kaul P. What is an optimal rate of early revascularization after ST-elevation myocardial infarction? insights from the GUSTO-V trial. Circulation. 2003;108(17):IV-613.
17. Lincoff AM, Califf RM, Ellis SG, et al; Thrombolysis and Angioplasty in Myocardial Infarction Study Group. Thrombolytic therapy for women with myocardial infarction: is there a gender gap? J Am Coll Cardiol. 1993;22(7):1780-1787.
18. Barron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation. 1998;97(12):1150-1156.
19. Chang WC, Kaul P, Westerhout CM, et al. Impact of sex on long-term mortality from acute myocardial infarction vs unstable angina. Arch Intern Med. 2003;163(20):2476-2484.
20. Vaccarino V, Krumholz HM, Yarzebski J, Gore JM, Goldberg RJ. Sex differences in 2-year mortality after hospital discharge for myocardial infarction. Ann Intern Med. 2001;134(3):173-181.
21. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM; National Registry of Myocardial Infarction 2 Participants. Sex-based differences in early mortality after myocardial infarction. N Engl J Med. 1999;341(4):217-225.
22. White RH, Beyth RJ, Zhou H, Romano PS. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107(5):414-424.
23. Petitti DB, Strom BL, Melmon KL. Prothrombin time ratio and other factors associated with bleeding in patients treated with warfarin. J Clin Epidemiol. 1989;42(8):759-764.
24. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation. 2001;103(19):2365-2370.
25. Blankenship JC, Hellkamp AS, Aguirre FV, Demko SL, Topol EJ, Califf RM. Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. Am J Cardiol. 1998;81(1):36-40.
26. Cho L, Topol EJ, Balog C, et al. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. J Am Coll Cardiol. 2000;36(2):381-386.
27. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44(3):E1-E211.
28. Van De Werf F, Adgey J, Ardissino D, et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716-722.
29. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358(9282):605-613.
30. Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2000;35(1):136-143.
31. Verhave JC, Balje-Volkers CP, Hillege HL, de Zeeuw D, de Jong PE. The reliability of different formulae to predict creatinine clearance. J Intern Med. 2003;253(5):563-573.
32. Alexander KP, Chen AY, Roe MT, et al; CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294(24):3108-3116.
33. Alexander KP, Chen AY, Newby LK, et al; CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Investigators. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation. 2006;114(13):1380-1387.
34. Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol. 2003;92(8):919-923.
35. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351(13):1285-1295.
36. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002;106(8):974-980.
37. Santopinto JJ, Fox KA, Goldberg RJ, et al; GRACE Investigators. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Heart. 2003;89(9):1003-1008.
38. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J. 2005;150(4):690-694.
39. McConnell JP, Branum EL, Ballman KV, Lagerstedt SA, Katzmann JA, Jaffe AS. Gender differences in C-reactive protein concentrations: confirmation with two sensitive methods. Clin Chem Lab Med. 2002;40(1):56-59.
40. Widmer A, Linka AZ, Attenhofer Jost CH, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99(1):25-31.
41. Kudriashova OIu, Zateishchikov DA, Barinov VG, et al. Gender differences in the state of the system of hemostasis in patients with ischemic heart disease [in Russian]. Kardiologiia. 2002;42(5):29-33.
42. Kalaria VG, Zareba W, Moss AJ, et al; THROMBO Investigators. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. Am J Cardiol. 2000;85(12):1401-1408.
43. Seiler C, Fleisch M, Garachemani A, Meier B. Coronary collateral quantitation in patients with coronary artery disease using intravascular flow velocity or pressure measurements. J Am Coll Cardiol. 1998;32(5):1272-1279.